Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ATRN-119, APR-1051, and the science of synthetic lethality make Aprea Therapeutics� disclosures a dense mix of oncology jargon and regulatory detail. If you’ve ever opened a 300-page 10-K only to hunt for clinical trial costs or royalty obligations, you know the challenge. Stock Titan’s platform decodes every line, turning "Aprea Therapeutics SEC filings explained simply" from wishful thinking into reality.
Our AI reads each submission the moment it hits EDGAR, then delivers plain-language highlights. Need to monitor "Aprea Therapeutics insider trading Form 4 transactions" before a data readout? Get instant alerts. Want the latest "Aprea Therapeutics quarterly earnings report 10-Q filing" broken down into cash burn, runway, and R&D spend? It’s ready within minutes. For deeper dives, we pair key biotech metrics with the exact page references so you can verify numbers without scrolling.
From "Aprea Therapeutics annual report 10-K simplified" to "Aprea Therapeutics 8-K material events explained," every filing type is covered:
- 10-K & 10-Q: drug development timelines, licensing agreements, and going-concern notes, plus "Aprea Therapeutics earnings report filing analysis."
- Form 4: "Aprea Therapeutics Form 4 insider transactions real-time" and "Aprea Therapeutics executive stock transactions Form 4" so you can track management’s conviction.
- DEF 14A: "Aprea Therapeutics proxy statement executive compensation" with side-by-side peer comparisons.
Analysts model trial milestones, portfolio managers flag dilution risk, and retail investors follow management buys. Whatever your goal, "understanding Aprea Therapeutics SEC documents with AI" starts here—complete coverage, timely updates, and clarity that lets you focus on the investment decision rather than the paperwork.
Sio Capital Management, LLC reports beneficial ownership of 279,369 shares of Aprea Therapeutics common stock, representing 5.05% of the class as of June 30, 2025. The position is held for affiliated funds for which Sio is the registered investment adviser; Sio reports 0 sole voting or dispositive power and 279,369 shared voting and dispositive power.
The 5.05% figure is calculated using 5,525,172 shares outstanding as of April 22, 2025. The filing notes that the general partner and Michael Castor may be deemed to have influence over the accounts that own the shares, while expressly disclaiming beneficial ownership; the filer certifies the shares are held in the ordinary course of business and not to change or influence control.
Aprea Therapeutics reported cash and cash equivalents of $16.5 million and total assets of $17.3 million, with an accumulated deficit of $328.2 million. The company recorded a net loss of $7.17 million for the six months and used $6.8 million of cash in operating activities over the same period. Grant revenue declined to $0.28 million year-to-date, largely from reduced NIH funding. Research and development spending was $4.40 million for six months, driven by ATRN-119 and APR-1051 programs, and the company expects safety/efficacy data in the second half of the year with RP2D decisions expected in the first half of 2026. Management states existing cash is not sufficient to fund operations for at least twelve months and has concluded substantial doubt exists about its ability to continue as a going concern, and is seeking additional funding.
Aprea Therapeutics furnished a press release that announces its financial results for the three- and six-month periods ended June 30, 2025 and provided an operational update. The press release is attached as Exhibit 99.1 and the company also updated its corporate presentation, filed as Exhibit 99.2. The Form 8-K states that the information in Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
The 8-K itself does not include the underlying financial figures or metrics; it notifies investors that the detailed results and presentation materials are available in the referenced exhibits.
FAQ
What is the current stock price of Aprea Therapeutics (APRE)?
What is the market cap of Aprea Therapeutics (APRE)?
